Year Founded
2017
Ownership
Public
Employees
~50
Stage
Phase 1
Modalities
Protein therapeuticsEngineered cytokines

Werewolf Therapeutics General Information

Conducting Phase 1/1b trials of WTX-124 as monotherapy and in combination with pembrolizumab in cutaneous melanoma, with full enrollment expected in 2025

Contact Information

Website
Primary Industry
Biotech
Corporate Office

Drug Pipeline

WTX-124
Phase 1
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Werewolf Therapeutics's pipeline data

Book a demo

Key Partnerships

Jazz Pharmaceuticals, Merck

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Werewolf Therapeutics Funding

Deal TypeDateAmountStatusStage
Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Werewolf Therapeutics's complete valuation and funding history, request access »

Werewolf Therapeutics Licensing Deals

AssetLicenseeDateTherapeutic Area
JZP898JazzApr 6, 2022Oncology
JZP898JazzApr 1, 2022Oncology
JZP898JazzApr 1, 2022Oncology
jzp898Jazz PharmaceuticalsApr 1, 2022Oncology
JZP898JazzInvalid Date
jzp898Jazz PharmaceuticalsApr 1, 2022Oncology
You're viewing 2 of 6 licensing deals. Get the full list »

Werewolf Therapeutics Investors

MPM Capital
Investor Type: Venture Capital
Holding: Minority